Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
2007-002939-90Phase 3Completed
- Sponsor
- Hormos Medical
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vaginal atrophy comparing Ospemifene 60 mg daily with Placebo (2 arms). Primary endpoint: Primary endpoint: change from baseline to Week 12 in efficacy measures. Started Jun 2007; status: completed.
02
Drugs
ospemifene
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on 2007-002939-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002939-90.